IceCure Advances Toward U.S. Approval for ProSense Cryoablation in Breast Cancer IceCure Medical (NASDAQ: ICCM) is making progress on the U.S. regulatory path for ProSense®, its liquid-nitrogen cryoablation system for early-stage, low-risk

(NASDAQ: #ICCM)
#IceCureMedical is nearing U.S. approval for ProSense cryoablation in breast cancer after a positive FDA review and plans for a key post-market study.
prismmarketview.com/icecure-adva...